Publikasjoner
Doktorgradsavhandling
Konferanseforedrag
Vitenskapelig artikkel
- Arne Carlsen; Øyvind Steinsbø; Jan Terje Kvaløy et al. (2025). Optimizing serum adalimumab levels in maintenance therapy via proactive therapeutic drug monitoring improves markers of disease activity in Crohn’s disease. (ekstern lenke)
- Tore Bjørn Grimstad; Arne Carlsen; Jan Terje Kvaløy et al. (2025). Fatigue in Inflammatory Bowel Disease: No Effect of Serum Concentrations of Infliximab, Adalimumab or Anti-Drug Antibodies During Maintenance Therapy. (ekstern lenke)
- Øyvind Steinsbø; Arne Carlsen; Ole Gunnar Aasprong et al. (2022). Histologic healing and factors associated with complete remission following conventional treatment in ulcerative colitis. (ekstern lenke)
- Tore Bjørn Grimstad; Berit Oterholm Mære; Jan Terje Kvaløy et al. (2021). The influence of disease activity on fatigue in patients with ulcerative colitis–a longitudinal study. (ekstern lenke)
- Tore Grimstad; Arne Carlsen; Lars Normann Karlsen (2019). Medikamentell behandling ved fistulerende Crohns sykdom. (ekstern lenke)
- Arne Carlsen; Tore Grimstad; Lars Normann Karlsen et al. (2019). A case of Menetriere's disease treated with the monoclonal antibody cetuximab. (ekstern lenke)
- Arne Carlsen; Roald Omdal; Lars Normann Karlsen et al. (2019). Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease. (ekstern lenke)
- Arne Carlsen; Roald Omdal; Kristian Øgreid Leitao et al. (2018). Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease. (ekstern lenke)
- Tore Grimstad; Katrine Brække Norheim; Jan Terje Kvaløy et al. (2016). Conventional treatment regimens for ulcerative colitis alleviate fatigue – an observational cohort study. (ekstern lenke)
- Jens Vikse; Daniel Limi Cacic; Arne Carlsen et al. (2016). En mann i 30-årene med ulcerøs kolitt og pancytopeni. (ekstern lenke)
- Tore Grimstad; Katrine Brække Norheim; Kjetil Isaksen et al. (2015). Fatigue in Newly Diagnosed Inflammatory Bowel Disease.. (ekstern lenke)